Literature DB >> 11532335

Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum.

J A Tzaferis1, J F McGinty.   

Abstract

The purpose of this study was to investigate the role that kappa opioid receptor stimulation has upon stimulant-induced behavior and neuropeptide gene expression in the striatum. Acute administration of amphetamine (2.5 mg/kg i.p.) caused an increase in behavioral activity and preprodynorphin, substance P, and preproenkephalin mRNA expression. When amphetamine-treated rats were pretreated with U69593, a kappa agonist (0.16 or 0.32 mg/kg s.c.), there was a significant decrease in behavioral activity. Quantitative in situ hybridization histochemistry revealed that 0.32 mg/kg U69593 significantly decreased amphetamine-induced mRNA expression of all three neuropeptides; however, only the induction of preproenkephalin mRNA was decreased by 0.16 mg/kg. These data suggest that stimulation of kappa receptors decreases acute amphetamine-induced behavior and mRNA expression of neuropeptides in the rat striatum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532335     DOI: 10.1016/s0169-328x(01)00178-4

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  12 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Age-dependent effects of kappa-opioid receptor stimulation on cocaine-induced stereotyped behaviors and dopamine overflow in the caudate-putamen: an in vivo microdialysis study.

Authors:  A M Cortez; S Charntikov; T Der-Ghazarian; L R Horn; C A Crawford; S A McDougall
Journal:  Neuroscience       Date:  2010-05-05       Impact factor: 3.590

Review 3.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

4.  Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens.

Authors:  Yan-fang Xia; Li He; Jennifer L Whistler; Gregory O Hjelmstad
Journal:  Neuropsychopharmacology       Date:  2007-06-06       Impact factor: 7.853

Review 5.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

6.  Differential time course of effects of kappa-opioid agonist treatment on dynorphin A levels and kappa-opioid receptor density.

Authors:  Claudio D'Addario; Manuela Di Benedetto; Sari Izenwasser; Sanzio Candeletti; Patrizia Romualdi
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice.

Authors:  A J Saylor; J F McGinty
Journal:  Genes Brain Behav       Date:  2008-08-04       Impact factor: 3.449

8.  Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.

Authors:  Melissa L Perreault; Dawn Graham; Sarah Scattolon; Yufang Wang; Henry Szechtman; Jane A Foster
Journal:  Psychopharmacology (Berl)       Date:  2007-07-10       Impact factor: 4.530

9.  KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.

Authors:  Paige M Estave; Mary B Spodnick; Anushree N Karkhanis
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Orvinols with mixed kappa/mu opioid receptor agonist activity.

Authors:  Benjamin M Greedy; Faye Bradbury; Mark P Thomas; Konstantinos Grivas; Gerta Cami-Kobeci; Ashley Archambeau; Kelly Bosse; Mary J Clark; Mario Aceto; John W Lewis; John R Traynor; Stephen M Husbands
Journal:  J Med Chem       Date:  2013-04-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.